(VIANEWS) – The NASDAQ opens in less than one hour and FibroGen‘s pre-market value is already 9.52% down.
FibroGen’s last close was $1.47, 92.97% below its 52-week high of $20.90.
The last session, NASDAQ ended with FibroGen (FGEN) dropping 31.94% to $1.47. NASDAQ rose 0.23% to $16,277.46, following the last session’s upward trend on what was a somewhat bullish trend trading session.
About FibroGen
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Earnings Per Share
As for profitability, FibroGen has a trailing twelve months EPS of $-2.92.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 49.4% and 55.6%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth declined by 21%, now sitting on 147.75M for the twelve trailing months.
Sales Growth
FibroGen’s sales growth for the current quarter is 14.5%.
More news about FibroGen (FGEN).
